Central China New Life (9983) Fundamentals 2026 — P/E 2.4x, Revenue Analysis | SniperIQ
Central China New Life (9983) is a CN-listed Real Estate company in Real Estate - Services with a market capitalization of HK$432M, trading at HK$0.34 on the HKSE. This SniperIQ fundamentals page covers Central China New Life's valuation (P/E 2.4x, P/B 0.2x), profitability (net margin 5.7%), revenue (¥2.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Central China New Life's market cap?
Central China New Life (9983) has a market capitalization of approximately HK$432M, trading at HK$0.34 on the HKSE. Market cap moves with the live share price.
What is Central China New Life's P/E ratio?
Central China New Life's trailing twelve-month P/E ratio is 2.4x, with a price-to-book (P/B) of 0.2x. Valuation multiples are best compared with Real Estate sector peers rather than read in isolation.
How profitable is Central China New Life?
Central China New Life runs a net profit margin of 5.7%, a gross margin of 19.6%, and an operating margin of 8.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Central China New Life generate?
Central China New Life reported revenue of ¥2.8B for fiscal year 2025, with net income of ¥157M and earnings per share (EPS) of 0.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Central China New Life pay a dividend?
Central China New Life offers a trailing dividend yield of about 31.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Central China New Life financially healthy?
Central China New Life carries a debt-to-equity ratio of 0.03x and a current ratio of 1.58x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Central China New Life a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Central China New Life (9983) the key facts are: market cap HK$432M, P/E 2.4x, revenue ¥2.8B, 52-week range 0.32-1.18. Weigh valuation, profitability, growth, and balance-sheet strength against Real Estate peers and form your own view.
Track Central China New Life's full fundamentals live
Get Central China New Life's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.